Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heike Reinhardt

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|April 24, 2014
PomalidomideMonika Engelhardt, Ralph Wäsch, Heike Reinhardt, et al.
Deutsches Arzteblatt International|April 25, 2017
Avoiding Errors in ChemotherapyStefanie Ajayi, Heike Reinhardt, Magdalena Szymaniak-Vits, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 2, 2013
Validation of the Freiburg Comorbidity Index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcomeMartina Kleber, Gabriele Ihorst, Barbara Gross, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|August 3, 2018
PomalidomideMonika Engelhardt, Stefanie Ajayi, Heike Reinhardt, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|August 3, 2018
RuxolitinibStefanie Ajayi, Heiko Becker, Heike Reinhardt, et al.
Haematologica|November 30, 2023
Comorbidity indices for prognostic evaluation in multiple myeloma: a comprehensive evaluation of the Revised Myeloma Comorbidity Index and other comorbidity indices with pro- and retrospective applicationsKatja Schoeller, Gabriele Ihorst, Heike Reinhardt, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 13, 2013
Prevalence of iron overload vs iron deficiency in multiple myeloma: resembling or different from MDS--and stem cell transplant (SCT)--patients?Christine König, Martina Kleber, Gabriele Ihorst, et al.
Cancer|June 1, 2021
Comparison of the prognostic significance of 5 comorbidity scores and 12 functional tests in a prospective multiple myeloma patient cohortSophia Scheubeck, Gabriele Ihorst, Katja Schoeller, et al.
Haematologica|May 2, 2018
Osteoprotective medication in the era of novel agents: a European perspective on values, risks and future solutionsMonika Engelhardt, Georg W Herget, Giulia Graziani, et al.
Annals of Hematology|September 21, 2024
Optimizing individualized therapy decision-making in multiple myeloma (MM): integration and impact of the Revised Myeloma Comorbidity Index in the MM-tumor boardEsther Dreyling, Gabriele Ihorst, Heike Reinhardt, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|April 24, 2014
PomalidomideMonika Engelhardt, Ralph Wäsch, Heike Reinhardt, et al.
Deutsches Arzteblatt International|April 25, 2017
Avoiding Errors in ChemotherapyStefanie Ajayi, Heike Reinhardt, Magdalena Szymaniak-Vits, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 2, 2013
Validation of the Freiburg Comorbidity Index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcomeMartina Kleber, Gabriele Ihorst, Barbara Gross, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|August 3, 2018
PomalidomideMonika Engelhardt, Stefanie Ajayi, Heike Reinhardt, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|August 3, 2018
RuxolitinibStefanie Ajayi, Heiko Becker, Heike Reinhardt, et al.
Haematologica|November 30, 2023
Comorbidity indices for prognostic evaluation in multiple myeloma: a comprehensive evaluation of the Revised Myeloma Comorbidity Index and other comorbidity indices with pro- and retrospective applicationsKatja Schoeller, Gabriele Ihorst, Heike Reinhardt, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 13, 2013
Prevalence of iron overload vs iron deficiency in multiple myeloma: resembling or different from MDS--and stem cell transplant (SCT)--patients?Christine König, Martina Kleber, Gabriele Ihorst, et al.
Cancer|June 1, 2021
Comparison of the prognostic significance of 5 comorbidity scores and 12 functional tests in a prospective multiple myeloma patient cohortSophia Scheubeck, Gabriele Ihorst, Katja Schoeller, et al.
Haematologica|May 2, 2018
Osteoprotective medication in the era of novel agents: a European perspective on values, risks and future solutionsMonika Engelhardt, Georg W Herget, Giulia Graziani, et al.
Annals of Hematology|September 21, 2024
Optimizing individualized therapy decision-making in multiple myeloma (MM): integration and impact of the Revised Myeloma Comorbidity Index in the MM-tumor boardEsther Dreyling, Gabriele Ihorst, Heike Reinhardt, et al.
Pageof 2